NCT00357721View on ClinicalTrials.gov

Atazanavir Twice Daily

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

June 30, 2006

Primary Completion Date

September 30, 2006

Study Completion Date

September 30, 2006

Conditions
HIV InfectionsProtease Inhibitor
Interventions
DRUG

Atazanavir Sulphate

Capsules, Oral, 200 mg, twice daily, 7 days.

DRUG

Atazanavir Sulphate

Capsules, Oral, 300 mg, twice daily, 8 days.

DRUG

Atazanavir Sulphate

Capsules, Oral, 400 mg, twice daily, 9 days.

Trial Locations (1)

Unknown

Local Institution, Hamilton

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY